LOS ANGELES, Dec. 13, 2013 (GLOBE NEWSWIRE) -- Response Genetics, Inc. (Nasdaq:RGDX) (the “Company”), a company focused on the development and sale of molecular diagnostic tests that help determine a patient’s response to cancer therapy, announced today it priced its previously announced underwritten public offering of 4,464,443 registered shares of its common stock, par value $0.01 per share, at a price of $1.20 per share. The Company plans to use the approximately $4,844,465 million in net proceeds of the offering for working capital and general corporate purposes. In connection with the offering, the Company has also granted the underwriter a 45-day option to purchase up to an additional 669,666 shares of common stock from the Company to cover over-allotments, if any.
Help employers find you! Check out all the jobs and post your resume.
